Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT03671629
Recruiting Not applicable

Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People

NCT03671629 · tracked via the Priya Life Science Sweden tracker
Sponsor
Umeå University
Phase
Not applicable
Started
2018-09-19
Last updated
2024-12-20

Condition(s) studied

Drug Use

Investigational drug(s) / intervention(s)

Enhanced clinical pharmacist service

Enhanced clinical pharmacist service: The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.

Study summary

This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients \>75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.

Eligibility

Sex
ALL
Min age
75 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Living at home * Acutely admitted * Registered at one of ten pre-specified primary care health centers Exclusion Criteria: * Patients unable to communicate or who do not speak Swedish * Patients scheduled for palliative care * Patients admitted due to intoxication by alcohol or drug (non prescription)

Primary outcome measure(s)

  • Time from discharge to first drug-related readmission — 180 days
    Survival analysis with drug-related readmission as endpoint

Trial sites (1)

FacilityCityRegionStatus
Medical Centre, University Hospital of Umeå Umeå Sweden Recruiting

More Umeå University trials in Sweden

The eHealth Diabetes Remission Trial Recruiting
Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression Active, not recruiting
Prognostic Factors in Periampullary Tumors and Cysts Recruiting
A Comparative Study of Stem and Cup Fixation and Polyethylene Wear Active, not recruiting
Abdominal Rectus Diastasis Microscopy and Rehabilitation (AMIRE) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03671629 on ClinicalTrials.gov ↗ ← All trials in Sweden